Skip to main content

Table 1 Characteristics of patients with KRAS and BRAF wild-type metastatic colorectal cancer treated with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab)

From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

 

All patients (n = 62)

FOLFOX + Cmab (n = 37)

XELOX + Cmab (n = 25)

P-value

No. women

28 (45.2 %)

18 (48.9 %)

10 (40.0 %)

0.502

Median (range) age (years)

66 (34–83)

67 (45–83)

66 (34–83)

0.769

ECOG performance status

  

0.885

 0

55 (88.7 %)

33 (89.2 %)

22 (88.0 %)

 

 1

7 (11.3 %)

4 (10.8 %)

3 (12.0 %)

 

Primary tumor site

   

0.193

 Colon

36 (58.1 %)

18 (48.6 %)

8 (32.0 %)

 

 Rectum

26 (41.9 %)

19 (51.4 %)

17 (68.0 %)

 

Metastatic site

    

 Liver

47 (75.8 %)

29 (78.4 %)

18 (72.0 %)

0.136

 Lymph node

18 (29.0 %)

13 (35.1 %)

5 (20.0 %)

 

 Lung

15 (24.2 %)

10 (27.0 %)

5 (20.0 %)

 

 Other

8 (12.9 %)

2 (5.4 %)

6 (24.0 %)

 
  1. Unless indicated otherwise, data show the number of patients in each group, with percentage in parentheses
  2. ECOG Eastern Cooperative Oncology Group